BioCentury
ARTICLE | Company News

TetraLogic, Merck deal

May 18, 2015 7:00 AM UTC

TetraLogic and Merck will jointly conduct a Phase I trial evaluating TetraLogic’s birinapant in combination with Merck’s Keytruda pembrolizumab to treat relapsed or refractory solid tumors. TetraLogic will fund the study, and Merck will provide Keytruda. The study is slated to begin late this year. ...